China's Duality Biologics, founded in 2020, has developed two-thirds of its clinical-stage antibody-drug conjugates by combining antibodies acquired from domestic peers with its proprietary linker-payload platform.

China’s Bio-Thera Solutions and Russia’s Pharmapark have struck a deal to expand their existing biosimilars collaboration for Russia and the Commonwealth of Independent States with a further candidate: the Chinese firm’s BAT2306 proposed secukinumab biosimilar to Cosentyx.

Also deals involving WuXi/Medigene, Eisai/Seed, Genor/Two River/Third Rock Ventures, ImmuneOnco/Instil, Biocytogen/Ideaya, Takeda/Dr Reddy’s/Zydus/Mankind and deals in brief.

As it reported mixed second-quarter earnings, South Korea's pharma industry is increasingly turning to obesity pipeline assets. Meanwhile, leadership disputes among family members within Hanmi are resurfacing.